Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Life After I-SPY Graduation: Neratinib Likely To Be Tested With Roche’s Perjeta

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

I-SPY 2 investigators are buoyed by “strong signal” for neratinib in high-risk subgroup in adaptive design study. Investors, however, are underwhelmed by results.

You may also be interested in...



I-SPY Graduates: Where Are They Now?

Five neoadjuvant breast cancer regimens have been tested successfully in I-SPY Phase II program, but three have not moved on to sponsor-driven pivotal testing and the I-SPY 3 master protocol has yet to be used.

I-SPY 2 Helping To Normalize Adaptive Trial Designs

Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.

Biomarkers Consortium Launches Adaptive Trial To Test Targeted Breast Cancer Drugs

The five-year I-SPY 2 study is a model for drug development and an innovative screening process for identifying winners, FDA's Woodcock says.

Topics

Related Companies

UsernamePublicRestriction

Register

PS005704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel